Get the Stockscreener App
53.79
0.28%
-0.15
After Hours:
53.50
-0.29
-0.54%
Sarepta Therapeutics Inc stock is traded at $53.79, with a volume of 1.91M.
It is down -0.28% in the last 24 hours and down -46.93% over the past month.
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
See More
Previous Close:
$53.94
Open:
$53.7
24h Volume:
1.91M
Relative Volume:
1.08
Market Cap:
$5.30B
Revenue:
$1.64B
Net Income/Loss:
$121.85M
P/E Ratio:
34.93
EPS:
1.54
Net Cash Flow:
$-480.40M
1W Performance:
+6.92%
1M Performance:
-46.93%
6M Performance:
-56.71%
1Y Performance:
-54.37%
1-Day Range:
$53.56
$55.49
1-Week Range:
$49.09
$56.34
52-Week Range:
$48.01
$173.25
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Name
Sarepta Therapeutics Inc
Sector
Industry
Phone
617-274-4000
Address
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
53.79 | 5.30B | 1.64B | 121.85M | -480.40M | 1.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-11-25 | Initiated | Wells Fargo | Overweight |
| Apr-02-25 | Upgrade | H.C. Wainwright | Sell → Neutral |
| Mar-31-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Nov-27-24 | Reiterated | Needham | Buy |
| Nov-25-24 | Initiated | H.C. Wainwright | Sell |
| Nov-07-24 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-21-24 | Initiated | Jefferies | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jul-29-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-26-24 | Downgrade | Citigroup | Buy → Neutral |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| May-28-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-14-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-13-23 | Resumed | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-21-23 | Initiated | Wedbush | Outperform |
| Oct-31-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-31-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-23-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-04-23 | Initiated | Citigroup | Buy |
| Mar-01-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-22-22 | Reiterated | BTIG Research | Buy |
| Dec-16-22 | Upgrade | UBS | Neutral → Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-05-22 | Reiterated | Needham | Buy |
| Dec-09-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-21 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Jan-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Jan-11-21 | Downgrade | UBS | Buy → Neutral |
| Jan-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Jan-08-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-20-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-31-20 | Initiated | Mizuho | Buy |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Aug-21-19 | Reiterated | Needham | Buy |
| Jul-09-19 | Reiterated | Morgan Stanley | Overweight |
| Jul-01-19 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-11-19 | Reiterated | Credit Suisse | Outperform |
| Oct-12-18 | Initiated | Bernstein | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-26-18 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-14-18 | Resumed | BofA/Merrill | Buy |
| Sep-06-18 | Initiated | Credit Suisse | Outperform |
| Aug-01-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-21-18 | Reiterated | Robert W. Baird | Outperform |
| Jun-20-18 | Reiterated | Needham | Buy |
| Jun-19-18 | Reiterated | H.C. Wainwright | Buy |
View All
Sarepta Therapeutics Inc Stock (SRPT) Latest News
Cancer Retains Top Spots In Alliance Deal Volume, Value - insights.citeline.com
Exploring 3 High Growth Tech Stocks In The US Market - Yahoo Finance
BofA Adjusts Price Target on Sarepta Therapeutics to $157 From $179, Keeps Buy Rating - marketscreener.com
FDA OKs trial of SRP-9005 gene therapy for LGMD type 2C - Muscular Dystrophy News
Sarepta loses CMO to RNA editing upstart; Another wave of personnel moves at Dyne - Endpoints News
Sarepta Therapeutics (NASDAQ:SRPT investor one-year losses grow to 54% as the stock sheds US$166m this past week - Yahoo Finance
Lobbying Update: $320,000 of SAREPTA THERAPEUTICS INC. lobbying was just disclosed - Nasdaq
Sarepta Therapeutics: Buy Rating Affirmed on Promising LGMD Program Progress and Regulatory Advancements - TipRanks
SRPT Provides Pipeline Updates on Rare Muscular Disorder Therapies - Zacks Investment Research
Sarepta (SRPT) Advances Gene Therapy Trials for Muscular Dystrop - GuruFocus
FDA clears Sarepta to proceed with LGMD gene therapy trials By Investing.com - Investing.com Nigeria
Sarepta Therapeutics Announces Pipeline Progress For Multiple Limb-Girdle Muscular Dystrophy Programs - MarketScreener
Sarepta Therapeutics Announces Pipeline Progress for Multiple Li - GuruFocus
FDA clears Sarepta to proceed with LGMD gene therapy trials - Investing.com
Sarepta Therapeutics (SRPT) Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs - StreetInsider
Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs - itemonline.com
Sarepta Expands Rare Disease Pipeline: FDA Green Light for New LGMD Trial - Stock Titan
Trump health policy uncertainty sends biotech sector into deeper slump - MarketScreener
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by O Shaughnessy Asset Management LLC - Defense World
Morgan Stanley Lowers Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $182.00 - Defense World
Wells Fargo Initiates Coverage of Sarepta Therapeutics (BMV:SRPT) with Overweight Recommendation - Nasdaq
SRPT Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta - Bluefield Daily Telegraph
Wells Fargo Initiates Coverage of Sarepta Therapeutics (SRPT) with Overweight Recommendation - Nasdaq
Wells Fargo Initiates Coverage of Sarepta Therapeutics (SRPT) wi - GuruFocus
Sarepta stock wins bullish view at Wells Fargo (SRPT:NASDAQ) - Seeking Alpha
Sarepta (SRPT) Price Target Cut by Morgan Stanley Ahead of Earni - GuruFocus
Cns Specific Antisense Oligonucleotide Market Is Booming - openPR.com
Wells Fargo Starts Sarepta (SRPT) with Overweight Rating, Targets $115 | SRPT Stock News - GuruFocus
Zacks Research Issues Pessimistic Forecast for SRPT Earnings - Defense World
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Sarepta Therapeutics (SRPT) Sees Price Target Reduction by Gugge - GuruFocus
The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb - Yahoo Finance
Q1 EPS Estimate for Sarepta Therapeutics Reduced by Analyst - Defense World
Around the Helix: Cell and Gene Therapy Company Updates – April 9, 2025 - CGTLive®
Independent DMC Concludes that Risk-Benefit Ratio for Sarepta’s DMD Gene Therapy Elevidys Remains Favorable - CGTLive®
NASDAQ: SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm - Business Wire
Sarepta (SRPT) Shares Fall Over 6% Following EMA Clinical Hold - GuruFocus
Sarepta (SRPT) Seeks Continuation of Elevidys Trials Amid Safety Review - GuruFocus
Sarepta Therapeutics (NASDAQ:SRPT) versus Cellectar Biosciences (NASDAQ:CLRB) Financial Analysis - Defense World
Sarepta Therapeutics Stock Falls as Some Trials Halted After Patient Death - MSN
NASDAQ: SRPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm - Financial Content
Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space - Seeking Alpha
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc.SRPT - PR Newswire
Can Solid Biosciences Challenge Sarepta in the DMD Market? - MarketBeat
3 Reasons to Avoid SRPT and 1 Stock to Buy Instead - Yahoo Finance
Investor Network: Sarepta Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
How to Take Advantage of moves in (SRPT) - news.stocktradersdaily.com
Sarepta stock holds neutral with $75 target at H.C. Wainwright By Investing.com - Investing.com South Africa
Sarepta stock target cut to $184 by Oppenheimer, retains Outperform - Investing.com South Africa
Oppenheimer Adjusts Price Target on Sarepta Therapeutics to $184 From $215, Keeps Outperform Rating - marketscreener.com
Sarepta Therapeutics Inc Stock (SRPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):